UPDATE: Scrip's World of Inflammation – what's new?
This article was originally published in Scrip
A lot has happened in the field of inflammatory diseases since Scrip published its popular World of Inflammation matrix of the key products and companies in December. So much so, that we have had to update it with all the latest movements to help you keep tabs on what's going on in this important therapy area.
You may also be interested in...
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.